New trials, publications, preprints and grants on this target, month by month.
Publication
Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis.
2 Nov 2026· ESMO open· PUBMED
Publication
Identification of biomarkers to guide treatment strategies toward precision medicine in hepatocellular carcinoma: Editorial on "ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling".
29 Oct 2026· Clinical and molecular hepatology· PUBMED
Publication
68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma.
24 Oct 2026· Drug design, development and therapy· PUBMED
Publication
A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.
12 Oct 2026· Future oncology (London, England)· PUBMED
Publication
Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.
1 Oct 2026· The Journal of clinical investigation· PUBMED
Trial
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
17 Sept 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.
11 Sept 2026· Journal of gynecologic oncology· PUBMED
Publication
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.
11 Sept 2026· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publication
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.
10 Sept 2026· Cell reports· PUBMED
Publication
Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.
7 Sept 2026· Diagnostics (Basel, Switzerland)· PUBMED
Publication
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.
21 Aug 2026· Cell reports. Medicine· PUBMED
Publication
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.
24 Jul 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.
14 Jul 2026· Translational lung cancer research· PUBMED
Publication
COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling".
1 Jul 2026· Clinical and molecular hepatology· PUBMED
Publication
ERBB3 Promotes Malignant Behaviors of Endometrial Cancer Cells with Involvement of the Ras-ERK/MAPK Signaling Pathway.
28 May 2026· Cancers· PUBMED
Publication
Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.
21 Apr 2026· Antibody therapeutics· PUBMED
Publication
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
15 Apr 2026· British journal of cancer· PUBMED
Publication
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.
7 Apr 2026· The Journal of clinical investigation· PUBMED
Publication
Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report.
28 Mar 2026· JTO clinical and research reports· PUBMED
Publication
[Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients].
26 Mar 2026· The Pan African medical journal· PUBMED
Publication
Oligodendrocyte-secreted ERBB3 Mediates the Competitive Uptake of Copper Ions by Tumor Cells to Promote Brain Metastasis in Lung Cancer.
25 Mar 2026· International journal of biological sciences· PUBMED
Publication
An integrated microfluidic system for automatic and self-validated analysis of cervical extracellular vesicle markers PD-L1 and ERBB3.
16 Mar 2026· Analytical sciences : the international journal of the Japan Society for Analytical Chemistry· PUBMED
Publication
The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.
13 Mar 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
HER3 and FOLR1 Expression as Actionable Targets in High-Grade Serous Ovarian Carcinoma: Prognostic and Therapeutic Implications.
5 Mar 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
Non-HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients.
1 Mar 2026· Diabetes/metabolism research and reviews· PUBMED
Publication
The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.
17 Feb 2026· International journal of molecular sciences· PUBMED
Trial
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
31 Jan 2026· PHASE2 · RECRUITING· CTGOV
Publication
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
27 Jan 2026· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publication
A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.
27 Jan 2026· Cellular oncology (Dordrecht, Netherlands)· PUBMED
Publication
Pattern of HER2 and HER3 Overexpression in Patients with Pancreatic Ductal Adenocarcinoma.
24 Jan 2026· Medicina (Kaunas, Lithuania)· PUBMED